Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
One task, one interaction, one pair, experts advocate
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
The facility is expected to become operational by FY2028-29
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Subscribe To Our Newsletter & Stay Updated